Roth Capital Has Negative Forecast for Accuray Q4 Earnings

Accuray Incorporated (NASDAQ:ARAY - Free Report) - Stock analysts at Roth Capital dropped their Q4 2025 earnings per share (EPS) estimates for Accuray in a research report issued on Thursday, May 1st. Roth Capital analyst J. Wittes now anticipates that the medical equipment provider will post earnings per share of $0.03 for the quarter, down from their prior estimate of $0.08. The consensus estimate for Accuray's current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray's FY2026 earnings at ($0.42) EPS.

Accuray (NASDAQ:ARAY - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.04. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. The firm had revenue of $113.24 million for the quarter, compared to the consensus estimate of $101.53 million.

Separately, StockNews.com lowered Accuray from a "buy" rating to a "hold" rating in a report on Monday.

Accuray Price Performance

Shares of ARAY traded up $0.02 on Monday, reaching $1.51. The stock had a trading volume of 125,834 shares, compared to its average volume of 672,443. Accuray has a twelve month low of $1.28 and a twelve month high of $2.95. The firm has a market capitalization of $155.25 million, a PE ratio of -30.20 and a beta of 1.30. The firm has a 50-day moving average of $1.65 and a 200 day moving average of $1.91. The company has a quick ratio of 0.88, a current ratio of 1.62 and a debt-to-equity ratio of 3.51.

Hedge Funds Weigh In On Accuray

Several hedge funds have recently added to or reduced their stakes in the business. Heartland Advisors Inc. increased its stake in shares of Accuray by 11.8% during the 1st quarter. Heartland Advisors Inc. now owns 4,274,750 shares of the medical equipment provider's stock worth $7,652,000 after purchasing an additional 450,000 shares in the last quarter. Renaissance Technologies LLC grew its holdings in Accuray by 6.8% during the 4th quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider's stock valued at $5,900,000 after buying an additional 189,414 shares during the last quarter. Geode Capital Management LLC increased its position in Accuray by 0.3% during the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider's stock worth $4,329,000 after buying an additional 6,758 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Accuray by 5.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,793,391 shares of the medical equipment provider's stock worth $3,551,000 after acquiring an additional 91,529 shares during the last quarter. Finally, Acuitas Investments LLC lifted its position in shares of Accuray by 100.4% in the first quarter. Acuitas Investments LLC now owns 1,420,207 shares of the medical equipment provider's stock valued at $2,542,000 after acquiring an additional 711,654 shares in the last quarter. 64.08% of the stock is currently owned by hedge funds and other institutional investors.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.